Ind-Swift Laboratories Q2 FY27 presentation: revenue ₹230.23 crore, PAT ₹31.03 crore, margin 18.02%
Q2 FY27 standalone revenue ₹230.23 crore with PAT ₹31.03 crore; management says operating income grew over 50% year on year and EBITDA margin reached 18.02%.
By ScoutQuest · · 1 min read
- Q2 FY27 standalone revenue
- ₹230.23 crore
- Q2 FY27 operating EBITDA
- ₹42.33 crore at an 18.02% margin
- Q2 FY27 PAT
- ₹31.03 crore at a 13.21% margin
- Period
- Q2 FY27
- Positioning
- Presents itself as a focused FDF manufacturer built on a net-debt-free balance sheet, a Global Business Unit present in 85+ countries, 3,000 domestic stockists and a pivot towards chronic ethical therapies.
📈 Q2 FY27 standalone revenue was ₹230.23 crore and total revenue ₹242.49 crore, up 25.18% quarter on quarter; operating EBITDA was ₹42.33 crore at an 18.02% margin and PAT ₹31.03 crore at a 13.21% margin. Management states that operating income grew over 50% year on year in the quarter, with margins lifted by mix and operating leverage.
📈 For H1 FY27 the standalone numbers were revenue of ₹416.35 crore and total revenue of ₹436.20 crore, up 31.83% year on year, while operating EBITDA rose 4.5x to ₹75.65 crore from ₹16.98 crore and PAT 3.3x to ₹55.47 crore from ₹16.88 crore. The company attributes the improvement to core operations, a lower raw material share of revenue and a shift towards higher-margin business.
📉 Working capital moved against the company over the half year: cash and cash equivalents fell to ₹322.81 crore from ₹388.31 crore, inventories rose to ₹168.35 crore from ₹102.83 crore and trade receivables to ₹234.79 crore from ₹168.53 crore. Management still describes the balance sheet as net-debt-free and says the ₹250 crore capex programme is funded through internal accruals.
🏭 The presentation lists FY27 revenue growth of more than 50%, a medium-term revenue CAGR of 20-25% and EBITDA margin expansion of 200-300 bps, with topline scaling from ₹636 crore to ₹1,500+ crore by FY30; it also says CDMO will deliver ₹200 to 220 crore over two years. As backing, it prints Atorvastatin export revenue of ₹8,549.74 lakh in FY26 versus ₹4,795.71 lakh in FY25 and cites 2,100+ dossiers shared and 540+ registrations owned.
Also from Ind-Swift Laboratories
Monitoring agency report on Rs.137.20 crore warrant proceeds: no deviation from stated objects
3 Nov 2026
Final monitoring agency report: preferential issue proceeds fully utilised, Rs. 58.99 crore shortfall flagged
3 Nov 2026
Ind-Swift Laboratories to hold Q2 FY27 earnings call on 4 November 2026 at 4:00 PM IST
30 Oct 2026
More numbers
- Revenue, Q2 FY27 standalone230.23 (INR Cr)
- Total operating EBITDA, Q2 FY2742.33 (INR Cr)
- PAT, Q2 FY2731.03 (INR Cr)
- Operating EBITDA margin, Q2 FY2718.02%
- Revenue, H1 FY27 standalone416.35 (INR Cr)
- PAT, H1 FY2755.47 (INR Cr)
- Total revenue year-on-year change, H1 FY2731.83%
- Cash & cash equivalents, H1 FY27322.81 (INR Cr)
- Capex programme₹250 crore
- Atorvastatin export revenue, FY268549.74 (INR Lakhs)
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.